 | | Vol. 12.24 – 22 June, 2021 |
| |
|
|
| The authors defined a transcriptional atlas of normal plasma cell (PC) development in secondary lymphoid organs, peripheral blood and bone marrow for comparison with the transcriptional programs of tumor PCs in amyloidosis and multiple myeloma.
[Blood] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| To examine the ontogeny and function of MS1 cells, researchers developed a cellular model for inducing CD14+ MS1 monocytes from healthy bone marrow hematopoietic stem and progenitor cells.
[Science Translational Medicine] |
|
|
|
| Scientists demonstrated the preclinical feasibility, efficacy, and toxicology of the β-globin gene correction in plerixafor-mobilized CD34+ cells from healthy and sickle cell disease patient donors.
[Science Translational Medicine] |
|
|
|
| Aberrant bone marrow-M1/M2 macrophage (MФ) polarization, characterized by increased M1 MФs and decreased M2 MФs and accompanied by impaired megakaryopoiesis-supporting abilities, was found in patients with thrombocytopenia post-allotransplant.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Stable ACC1 protein expression suppressed the growth-promoting activity and increased ROS levels with the consumption of NADPH in a primary bone marrow culture, and delayed the onset of acute myeloid leukemia with increases in mature myeloid cells in mouse models.
[Journal of Clinical Investigation] |
|
|
|
| Single-cell RNA sequencing across ezh1 genotypes revealed a dropout of ezh1+/− cells among arterial endothelium associated with positive regulation of gene transcription.
[Stem Cell Reports] |
|
|
|
| Investigators developed a novel class of ice-interactive cryoprotectants for the cryopreservation of HSCs. The corresponding DMSO-, protein-, and serum-free cryopreservation media candidates were screened through a series of biological assays using human cell lines, peripheral blood cells, and bone marrow cells.
[Bone Marrow Transplantation] |
|
|
|
| Researchers investigated whether bone marrow-derived cells (BMDCs) could be applied as gene carriers for cell-based gene therapy by employing the accumulation of BMDCs in a mouse model of amyotrophic lateral sclerosis (ALS).
[Scientific Reports] |
|
|
|
| | In this cohort study of 966 patients with hematologic cancer and COVID-19, after adjustment for potential confounding factors, convalescent plasma treatment was associated with a significantly improved 30-day mortality in the 143 individuals who received it.
[JAMA Oncology] |
|
|
|
| The authors prospectively investigated frequency and clinical associations of clonal hematopoiesis (CH) in 200 patients without known hematologic disease undergoing total hip arthroplasty. Prevalence of CH was 50%, including 77 patients with CH of indeterminate potential, and 23 patients harboring CH with lower mutation burden.
[Blood] |
|
|
|
| Investigators reported an integrated analysis of 3D genome alterations and differential gene expressions in eighteen newly diagnosed T-lineage acute lymphoblastic leukemia patients and four healthy controls. Patients with HOXA11-A13 expressions, but not other genes in the HOXA cluster, had immature immunophenotype and poor outcomes.
[Nature Communications] |
|
|
|
| Researchers discussed the effective implementation of available therapeutic measures and appropriate disease monitoring of core-binding factor acute myelogenous leukemia.
[Blood Cancer Journal] |
|
|
|
|
| Investigators review how major sources of systemic inflammation act on and subsequently shape HSC fate and function. They highlight how lifelong inflammatory exposure contributes to HSC inflammatory-aging and the selection of premalignant HSC clones.
[Journal of Experimental Medicine] |
|
|
|
| The authors discuss the requirements, potential, and limitations of the different current technologies for the analysis of hematopoietic stem and progenitor cell signaling and its effect on cell fates.
[Journal of Experimental Medicine] |
|
|
|
| Scientists summarize the current understanding of hematopoietic niches, review recent progress, and identify important unresolved questions.
[Developmental Cell] |
|
|
|
|
| Salarius Pharmaceuticals, Inc. announced the initiation of a clinical trial to investigate seclidemstat, a novel lysine specific demethylase 1 inhibitor, as a potential treatment for hematologic cancers. This investigator-initiated Phase I/II trial will be led by Dr. Guillermo Montalban-Bravo from the The University of Texas MD Anderson Cancer Center.
[Salarius Pharmaceuticals, Inc.] |
|
|
|
| Nanjing Bioheng Biotech Co., Ltd. announced UCAR T cell therapy product targeting CD7, received Orphan Drug Designation from the US FDA for the treatment of T-cell acute lymphoblastic leukemia (T-ALL).
[Bioheng Biotech Co., Ltd. (PR Newswire, Inc.)] |
|
|
|
|
| September 13 – 15, 2021
Virtual |
|
|
|
|
|
| | Cyprus Cancer Research Institute – Nicosia, Cyprus |
|
|
|
| | Stanford University – Stanford, California, United States |
|
|
|
| | University of Wisconsin Madison – Madison, Wisconsin, United States |
|
|
|
| | UT Southwestern Medical Center – Dallas, Texas, United Statess |
|
|
|
| | Memorial Sloan Kettering Cancer Center – New York, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
